Compare NCNO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | NVAX |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2022 | 1996 |
| Metric | NCNO | NVAX |
|---|---|---|
| Price | $17.76 | $9.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 9 |
| Target Price | ★ $26.07 | $11.33 |
| AVG Volume (30 Days) | 3.9M | ★ 4.4M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 115.15 | ★ 309.76 |
| EPS | ★ 0.12 | N/A |
| Revenue | $594,781,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $9.53 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $147.92 | ★ N/A |
| Revenue Growth | 10.01 | ★ 64.69 |
| 52 Week Low | $13.80 | $6.20 |
| 52 Week High | $33.92 | $11.85 |
| Indicator | NCNO | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 56.88 |
| Support Level | $14.04 | $7.99 |
| Resistance Level | $18.65 | $10.09 |
| Average True Range (ATR) | 0.89 | 0.56 |
| MACD | 0.35 | 0.06 |
| Stochastic Oscillator | 90.91 | 79.73 |
Ncino Inc is a provider of cloud-based software for financial institutions. It is focused on developing the nCino Platform to transform commercial and small business lending for community and regional banks in the U.S. With the company's platform financial institutions can Operate More Intelligently, Improve Efficiency, Elevate Employee and Client Experiences, and Manage Risk and Compliance Continuously Rather Than Reactively. It has built and acquired technology, including SimpleNexus, DocFox, FullCircl, ILT, Visible Equity, FinSuite, and Sandbox Banking, to augment the nCino Platform's capabilities for mortgage lending, onboarding, account opening, indirect auto lending, and analytics and AI. The company operates as one operating segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.